Novartis in Slovenia is joining Movember thus raising awareness of prostate cancer
- In November, Novartis in Slovenia is joining the international Movember movement, aimed at raising awareness of prostate cancer and other health-related issues experienced by men.
- Novartis in Slovenia prepared number of awareness activities for their associates; they’re also invited to schedule an appointment for prostate-specific antigen (PSA) measurement free of charge.
- Novartis is the only pharmaceutical company which is pursuing four different cancer treatment platforms and is also pursuing new breakthrough solutions for cancer patients.
November is traditionally focusing on health-related issues, experienced by men, especially of prostate cancer, and in recent years also to mental health and suicide. Prostate cancer is the most commonly diagnosed cancer in men. It usually affects men above the age of 50, while now it is more and more commonly diagnosed in younger males, as well. According to the predictions of the World Health Organization, every sixth man will get prostate cancer. Due to further ageing of the population, the number of those with the disease will most likely increase.1
In November, Novartis in Slovenia will join the international Movember movement. The company prepared several awareness activities for their associates, such as professional lectures, meetings and online podcasts with specialists from different fields - oncology and urology specialists and other guests. During the month, associates are also encouraged to schedule an appointment for prostate-specific antigen (PSA) measurement, which will be free of charge for them. »This year, we are joining Movember on several levels, which are aimed to raise awareness among our associates and their families about prostate cancer and other similar diseases. We were additionally motivated to join Movember by the story of our colleague Andrej Rupar, who was diagnosed with prostate cancer at one of the company’s health check-ups. Because of this experience, we are even more aware of the importance of prevention and awareness in work environment,« said Katarina Klemenc, Head Communications and Patient Engagement in Novartis Slovenia.
Patient associations play an exceptional role in providing the right information and assistance to patients and their caregivers. That is why Novartis in Slovenia also supports the Slovenian Oncology Society for Men OnkoMan. This year, the funds were donated to two of their programs - the Circle of Life and their awareness campaign "30 seconds can save your life", which raises awareness of the importance of early detection of testicular cancer.
Novartis with breakthrough solutions in oncology
Novartis is the only pharmaceutical company which is pursuing four different cancer treatment platforms. These include radioligand therapy, cell and gene therapy, targeted therapy and immunotherapy, with an opportunity to combine these platforms for the best outcomes for cancer patients. Among other, Novartis is also looking for solutions for treatment with radioligand therapy in patients with advanced prostate cancer. With Metastatic Castration-Resistant Prostate Cancer (mCRPC), the tumor spreads to other parts of the body, such as neighboring organs or bones and remains unresponsive to hormone treatment. The five-year survival rate for patients with mCRPC is approximately 15%, so therefore, the need for new treatment options is enormous2. The new therapeutic approach allows targeted delivery of radiation to the tumor, while limiting damage to surrounding normal tissue. As part of Movember activities. Maurizio Mariani, Head of RLT Research at Novartis Institutes for BioMedical Research, will held web lecture on new treatment possibilities for patients with advanced prostate cancer.
1. Slovenian Association ofOncology patients. Prostate cancer. Available at: http://www.onkologija.org/o-raku/rak-prostate/#1490093507434-7ddd96b9-a83cb35e-8c2d(Retrieved October 2021).
2. Novartis announces positiveresult of phase III study with radioligand therapy 177Lu-PSMA-617 in patientswith advanced prostate cancer. Na voljo na: https://www.novartis.com/news/media-releases/novartis-announces-positive-result-phase-iii-study-radioligand-therapy-177lu-psma-617-patients-advanced-prostate-cancer (Retrieved October 2021).
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. Novartis is the leading provider of medicines in Slovenia, operating through Novartis Pharma Services Inc., Podružnica v Sloveniji, Lek and Sandoz. Find out more at www.novartis.com.
This press release contains statements and conclusions based on projections of the future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.
For more information please contact:
Head Communications and Patient Engagement
Phone: +386 1 580 22 43